 |
|
Carbohydrate restriction may slow prostate tumor growth
May 27, 2009DURHAM, N.C. -- Restricting carbohydrates, regardless of weight loss, appears to slow the growth of prostate tumors, according to an animal study being published this week by researchers in the Duke Prostate Center.
"Previous work here and elsewhere has shown that a diet light in carbohydrates could slow tumor growth, but the animals in those studies also lost weight, and because we know that weight loss can restrict the amount of energy feeding tumors, we weren't able to tell just how big an impact the pure carbohydrate restriction was having, until now," said Stephen Freedland, M.D., a urologist in the Duke Prostate Center and lead investigator on this study.
The researchers believe that insulin and insulin-like growth factor contribute to the growth and proliferation of prostate cancer, and that a diet devoid of carbohydrates lowers serum insulin levels in the bodies of the mice, thereby slowing tumor growth, Freedland said.
The findings appear in the May 26, 2009 online edition of the journal Cancer Prevention Research. Funding was provided by the United States Department of Veterans Affairs, the Department of Defense Prostate Cancer Research Program; the American Urological Association/ Foundation Astellas Rising Star in Urology Award, and the Robert C. Atkins Foundation.
Animals in the study were fed one of three diets: a very high fat/ no carbohydrate diet; a low-fat/ high carbohydrate diet; and a high fat/ moderate-carbohydrate diet, which is most similar to the "Western" diet most Americans eat, Freedland said. They were then injected with prostate tumors at the same time.
"The mice that were fed a no-carbohydrate diet experienced a 40 to 50 percent prolonged survival over the other mice," Freedland said.
Mice on the no-carbohydrate diet consumed more calories in order to keep body weights consistent with mice on the other study arms.
"We found that carbohydrate restriction without energy restriction - or weight loss - does indeed result in tumor growth delay," he said.
The researchers plan to begin recruiting patients at two sites - Duke and the University of California - Los Angeles - for a clinical trial to determine if restricting carbohydrate intake in patients with prostate cancer can similarly slow tumor growth. The trial should begin within a few weeks.
"It's very exciting - this is a potential new mechanism to fight prostate cancer growth and help patients live longer with their disease," Freedland said.
Duke University Medical Center
The findings appear in the May 26, 2009 online edition of the journal Cancer Prevention Research. Funding was provided by the United States Department of Veterans Affairs, the Department of Defense Prostate Cancer Research Program; the American Urological Association/ Foundation Astellas Rising Star in Urology Award, and the Robert C. Atkins Foundation.
Animals in the study were fed one of three diets: a very high fat/ no carbohydrate diet; a low-fat/ high carbohydrate diet; and a high fat/ moderate-carbohydrate diet, which is most similar to the "Western" diet most Americans eat, Freedland said. They were then injected with prostate tumors at the same time.
"The mice that were fed a no-carbohydrate diet experienced a 40 to 50 percent prolonged survival over the other mice," Freedland said.
Mice on the no-carbohydrate diet consumed more calories in order to keep body weights consistent with mice on the other study arms.
"We found that carbohydrate restriction without energy restriction - or weight loss - does indeed result in tumor growth delay," he said.
The researchers plan to begin recruiting patients at two sites - Duke and the University of California - Los Angeles - for a clinical trial to determine if restricting carbohydrate intake in patients with prostate cancer can similarly slow tumor growth. The trial should begin within a few weeks.
"It's very exciting - this is a potential new mechanism to fight prostate cancer growth and help patients live longer with their disease," Freedland said.
Duke University Medical Center
Tumor Growth Current Events and Tumor Growth News RSSCancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
Laser therapy can aggravate skin cancer
High irradiances of low-level laser therapy (LLLT) should not be used over melanomas.
Common pain relief medication may encourage cancer growth
Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.
Cancers' Sweet Tooth May Be Weakness
The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.
Researchers 'notch' a victory toward new kind of cancer drug
Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed.
New mechanism explains how the body prevents formation of blood vessels
Researchers at Uppsala University, in collaboration with colleagues in Sweden and abroad, have identified an entirely new mechanism by which a specific protein in the body inhibits formation of new blood vessels.
CSHL study shows that some malignant tumors can be shut down after all
Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53.
Hundreds of genes distinguish patients likely to survive advanced melanoma
Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
Early-stage, HER2-positive breast cancer patients at increased risk of recurrence
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.
More Tumor Growth Current Events and Tumor Growth News Articles
 |
Cancer Immunotherapy: Immune Suppression and Tumor Growth by George C. Prendergast (Editor), Elizabeth M. Jaffee (Editor) There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait... |
|
No. 571(Tumors, Growths) 1 oz by PROGRESSIVE LABS | |
 |
Charlie Rose with Anthony Robbins (July 19, 2000) Motivational speaker Anthony Robbins on his unusual career advising everyone from Andre Agassi and President Clinton to the IBM Corporation and the United States Army and the launch of his new website, www.dreamlife.com. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Intracranial Tumor Canvas Print - Canvas Art by FineArtAmerica.com This is a beautiful stretched-canvas art print wrapped on 2.5" thick stretcher bars. The print is professionally printed, assembled, and shipped within 2 - 3 business days from our production facility in North Carolina and arrives ready-to-hang on your wall. FineArtAmerica.com is home to more than 20,000 artists from all over the world who entrust us to fulfill their print orders online. We offer a 30-day money-back guarantee on every print that we sell and look forward to helping you select your next piece. |
 |
Olympian Labs Ip-6, Inositol Hexaphosphate by Olympian Labs Inositol hexaphosphate is a sugar molecule attached to six phosphate molecules. It is found throughout nature, in wheat and rice bran, legumes such as soybeans and virtually every kind of mammalian cell. It plays an important role in regulating vital cellular functions including cell proliferation and differentiation. There has been research on human liver cancer cells that were treated with inositol hexaphosphate and transplanted into mice. They found that inositol hexaphosphate slowed or stopped the growth of liver cancer cells and shrank existing tumors three- to four-fold. Inositol hexaphosphate does not kill cancer cells - it tames them and makes them behave like normal cells. Inositol hexaphosphate decreases proliferation of cancer cells and causes them to differentiate,... |
 |
Growth Factors and Tumor Promotion: Implications for Risk Assessment by Tex.) International Conference on Carcinogenesis and Risk Assessment (7th : 1993 : Austin (Author), Thomas J. Slaga (Editor), Robert Leboeuf (Editor), Henry Pitot (Editor), R. Michael McClain (Editor) Hoffman LaRoche, Inc., Nutley, New Jersey. Proceedings of the Seventh International Conference on Carcinogenesis and Risk Assessment held December 1-4, 1993, in Austin, Texas. |
|
Two drugs halted tumor growth in lung cancer.(Clinical Rounds): An article from: Family Practice News by Erik L. Goldman (Author) This digital document is an article from Family Practice News, published by International Medical News Group on September 1, 2004. The length of the article is 595 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Two drugs halted tumor growth in lung cancer.(Clinical Rounds) Author: Erik L. Goldman Publication: Family Practice News (Magazine/Journal) Date: September 1, 2004 Publisher: International Medical News Group Volume: 34 Issue: 17 Page: 60(1) Distributed by Thomson... | |
|
Peregrine's phospholipid-targeted antibodies fused wth cytokines reduce tumor growth.: An article from: BIOTECH Patent News by Gale Reference Team (Author) This digital document is an article from BIOTECH Patent News, published by Thomson Gale on September 1, 2006. The length of the article is 654 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Peregrine's phospholipid-targeted antibodies fused wth cytokines reduce tumor growth. Author: Gale Reference Team Publication: BIOTECH Patent News (Newsletter) Date: September 1, 2006 Publisher: Thomson Gale Volume: 20 Issue: 9 Distributed by Thomson... | |
|
Mechanism of tumor growth in crowngall by Erwin F Smith (Author) | |
|
Influence of the Host on Tumor Development (Cancer Growth and Progression) by Ronald B. Herberman (Editor) X |
| © 2009 BrightSurf.com |